News for Ovid Therapeutics Inc. (OVID)

**media[570620]**

Ovid Therapeutics (OVID) delivered earnings and revenue surprises of 18.75% and 45.71%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors; two industry veterans joined management team as Ovid prepares to t

**media[563181]**

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. ( OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for

NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. ( OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions

Madison Avenue Partners, LP (Trades, Portfolio), a prominent investment firm, recently executed a significant transaction involving Ovid Therapeutics Inc. On De

Oppenheimer has upgraded Ovid Therapeutics (OVID) to outperform from perform, citing its drug candidate OV329. Read more here.

Two preclinical studies to be presented on OV329, a potential next-generation GABA aminotransferase inhibitor, highlighting its safety profile and lack of ocula

Analysis-RFK Jr vow to purge FDA sets up collision with Big Pharma

Ovid Therapeutics (OVID) delivered earnings and revenue surprises of -5.26% and 15.33%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Marinus reports positive phase 3 seizure treatment trial results

Marinus Pharmaceuticals' patent upheld by PTAB

Ovid stock gets boost from promising OV329 toxicity profile - B.Riley

Ovid reports promising safety profile for epilepsy drug OV329

Oppenheimer sees upside for Marinus Pharmaceuticals stock ahead of key trial results

NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of...

Ovid Therapeutics (OVID) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

This week, once again, companies across the biotech sector continued to re-evaluate their pipelines and trim their workforces in a bid to conserve cash and extend their financial runway.